11:26 AM EST, 12/17/2024 (MT Newswires) -- Lipocine ( LPCN ) said Tuesday that LPCN 1148 has received fast track designation from the US Food and Drug Administration as a treatment for sarcopenia in patients with decompensated cirrhosis.

Sarcopenia is a debilitating complication in patients with decompensated cirrhosis, an end-stage liver disease.

The Fast Track program helps accelerate the development and expedite the review of products that are meant to treat serious diseases and for which there is an unmet medical need.

Price: 5.01, Change: +0.02, Percent Change: +0.34